Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02390089 · ClinicalTrials.gov registry record · Phase 1
Cough According to Stimulus Type in PD
A Phase 1 study, sponsored by University of Florida.
- Completed
- Registry status
- Phase 1
- Development phase
- 158
- Enrollment target
NCT02390089 is a Phase 1 study that has completed, run by University of Florida. The registered enrollment target is 158 participants.
The verdict
NCT02390089, a Phase 1 study, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 158 participants
- Enrollment target
Study Summary
Aspiration pneumonia (APn) occurs at a higher rate in patients with Parkinson's disease (PD) versus healthy adults. This is of particular public health concern given that death secondary to aspiration pneumonia and lung infection is a leading cause of death in persons with PD. Swallowing and cough function are affected in PD, putting people with PD at significant risk for uncompensated aspiration (aspiration without adequate cough response). One challenge in the management of airway protective deficits related to PD is the chronic and progressive nature of the disease, where swallowing dysfunction appears subtly in the form of microaspiration, reducing the perceived urgency of the swallowing disorder by both clinicians and patients. The long-term goal of this research is to advance the management of airway protection deficits in patients with neurodegenerative disease in order to decrease morbidity and mortality due to aspiration related lung infection. The objective here is to further specify deficits leading to uncompensated airway compromise in PD in order to advance the clinical management of these patients, leading to an immediate positive impact.
Interventions
- DRUG Capsaicin vapor
- OTHER fog
- RADIATION Videofluoroscopic swallow evaluation
- DEVICE Nebulizer
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 158 participants |
| Start Date | 2015-04 |
| Est. Completion | 2019-02-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02390089
The ClinicalTrials.gov registry entry for NCT02390089 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 158 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Capsaicin vapor is the first listed.
NCT02390089 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02390089 about?
NCT02390089 is a clinical study titled "Cough According to Stimulus Type in PD". Aspiration pneumonia (APn) occurs at a higher rate in patients with Parkinson's disease (PD) versus healthy adults. This is of particular public health concern given that death secondary to aspiration pneumonia and lung infection is a leading cause of death in persons with PD. Swallowing and cough f...
What is the current status of trial NCT02390089?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 158 participants. The study started on 2015-04. Estimated completion is 2019-02-13.
What interventions are being tested in trial NCT02390089?
The interventions under investigation include: Capsaicin vapor (DRUG), fog (OTHER), Videofluoroscopic swallow evaluation (RADIATION), Nebulizer (DEVICE).
Who is sponsoring clinical trial NCT02390089?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.